Mesa Labs Q1 FY2027: Revenue Edges Up 1%, Operating Income More Than Doubles

summarizeSummary

Mesa Labs' Q1 FY2027 revenue rose 1% to $60.1M, operating income more than doubled to $7.0M, and cash from operations jumped to $14.7M, allowing significant debt paydown.

check_boxKey Events · Earnings and Guidance · MLAB

• Revenue Up 1%

  Q1 FY2027 revenue reached $60.1 million, a 1% increase from $59.5 million in the prior year, driven by Calibration Solutions (+7.6%) and Biopharmaceutical Development (+5.0%).

• Operating Income More Than Doubles

  Operating income surged to $7.0 million from $3.1 million, reflecting cost reductions and gross margin improvement to 64.9% from 62.0%.

• Cash Flow Strength Enables Debt Reduction

  Cash from operations was $14.7 million, up from $1.9 million, allowing $8.7 million in net debt repayments. Revolver balance reduced to $77.3 million.

• Net Income Down on Prior-Year FX Gain

  Net income of $2.8 million vs $4.7 million; prior year included a $6.1 million unrealized foreign currency gain. Effective tax rate rose to 35.0%.

auto_awesomeAnalysis · MLAB · Industrial Applications And Services

Mesa Laboratories kicked off fiscal 2027 on a solid note, posting revenue of $60.1 million—a 1% year-over-year increase—fueled by gains in Calibration Solutions and Biopharmaceutical Development. Cost-containment efforts and a healthier gross margin propelled operating income to $7.0 million, more than double the prior year's $3.1 million. Net income, however, slipped to $2.8 million from $4.7 million, though the earlier period had benefited from a $6.1 million foreign currency gain. A surge in cash from operations to $14.7 million enabled $8.7 million in debt reduction, and the company remains in full compliance with its debt covenants while seeing no goodwill impairment. Operational progress is evident, but the lower net income and elevated effective tax rate keep the momentum in check.